STOCK TITAN

Accuray Incorp SEC Filings

ARAY Nasdaq

Welcome to our dedicated page for Accuray Incorp SEC filings (Ticker: ARAY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Accuray’s radiation oncology business is packed with regulatory nuance—each 10-K page covers FDA clearances, global supply chains, and service-contract margins. Finding R&D spend or tracking when executives trade shares should not require hours with spreadsheets. That’s why our SEC filings hub brings Accuray insider trading Form 4 transactions and every other disclosure into one streamlined view.

Stock Titan’s AI reads the fine print for you. Open an Accuray quarterly earnings report 10-Q filing and our algorithms instantly surface backlog changes, CyberKnife unit shipments, and reimbursement commentary. Get Accuray Form 4 insider transactions real-time alerts, side-by-side with revenue trend graphs. Whether you’re understanding Accuray SEC documents with AI for due diligence or need an Accuray annual report 10-K simplified, we translate technical jargon into clear business drivers.

Every filing type is here and searchable: 8-Ks for product-recall updates—see “Accuray 8-K material events explained”—DEF 14A for Accuray proxy statement executive compensation, and of course Form 4 for Accuray executive stock transactions Form 4. Use our AI-powered summaries to compare quarter-over-quarter margin shifts, monitor clinical-trial timelines, and flag warranty reserve changes. With comprehensive coverage, real-time EDGAR pulls, and plain-English insights, you’ll move from document download to actionable perspective in minutes while enjoying Accuray SEC filings explained simply and fast Accuray earnings report filing analysis.

Rhea-AI Summary

Accuray Incorporated reported results from its 2025 Annual Meeting of Stockholders. Stockholders elected three Class I directors — Anne B. Le Grand, Joseph E. Whitters and Chan W. Galbato — to serve until the 2028 annual meeting, each receiving more votes for than against. Stockholders also approved the Company’s 2026 Equity Incentive Plan, with 54,189,859 shares in favor and 8,102,765 against, allowing Accuray to continue granting equity-based awards to employees and directors. In an advisory vote, stockholders approved compensation for the Company’s named executive officers, and they ratified the appointment of Grant Thornton LLP as independent registered public accounting firm for the fiscal year ending June 30, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Summary

Accuray Inc. director Robert Kill reported the conversion of 56,603 restricted stock units into common stock on 11/13/2025 at an exercise price of $0 per share. Following this transaction, he beneficially owned 162,809 shares of Accuray common stock directly. The RSUs were originally scheduled to vest 100% on 11/21/2025, but the vesting and settlement into shares were accelerated to 11/13/2025 in connection with his retirement from the Board of Directors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Accuray Inc. director reports no share ownership. A director of Accuray Inc. (ARAY) has filed a beneficial ownership report stating that no securities of the company are beneficially owned. The filing confirms that the individual serves as a director but does not currently hold Accuray common stock or derivative securities such as options or warrants.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

Accuray (ARAY) filed its quarterly report showing a wider loss amid higher financing costs and softer product demand. Net revenue was $93.9 million, down from $101.5 million a year ago, as product sales fell while services grew. Gross profit declined to $26.5 million. Operating expenses were $37.9 million, and interest expense rose to $8.1 million, reflecting the new credit facilities and paid‑in‑kind interest. The company recorded a $1.9 million non‑cash loss from warrant remeasurement.

Accuray reported a net loss of $21.7 million (−$0.18 per share) versus a $4.0 million loss last year. Operating cash flow improved to $12.2 million, supported by accounts receivable collections, while inventories increased. Cash and cash equivalents were $63.3 million; total assets were $456.8 million and stockholders’ equity was $61.9 million. The company ended the quarter with $167.5 million of debt outstanding (net carrying value $140.2 million) and remained in compliance with debt covenants. Remaining performance obligations totaled $866.0 million. Management initiated a restructuring, eliminating about 3% of the workforce and recording $1.5 million in severance and $1.3 million in consulting costs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.07%
Tags
quarterly report
-
Rhea-AI Summary

Accuray Incorporated furnished an 8‑K announcing its fiscal 2026 first quarter results. The company provided a press release for the quarter ended September 30, 2025, and made an investor presentation available.

The materials were furnished under Item 2.02 and Item 7.01 and are not deemed filed. The press release is attached as Exhibit 99.1, and the earnings call presentation as Exhibit 99.2. The presentation will also be available on Accuray’s investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.07%
Tags
current report
-
Rhea-AI Summary

Accuray (ARAY)1,250,000 Restricted Stock Units (RSUs) and 1,250,000 Performance Stock Units (PSUs), each unit representing the right to receive one share of common stock.

The RSUs vest in four equal tranches, with 25% on each of the first, second, third, and fourth anniversaries of the grant date. The PSUs vest upon Accuray’s common stock achieving a specified price per share during designated performance periods. Following the reported transactions, 1,250,000 RSUs and 1,250,000 PSUs are shown as beneficially owned, held directly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

Accuray Inc. (ARAY) reported an insider ownership update. Stephen R. La Neve—identified as both CEO and Director—filed a Form 3 with an event date of 10/20/2025, stating that no securities are beneficially owned.

Form 3 is an initial statement of beneficial ownership for company insiders. This filing is administrative and indicates that, as of the event date, the reporting person did not hold Accuray equity or derivative positions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Accuray (ARAY) reported an officer transaction tied to RSU settlement on 10/31/2025. The filer acquired 37,500 shares of Common Stock at $0 via transaction code M and had 12,001 shares withheld at $1.41 under code F to cover taxes. Following these entries, the officer beneficially owned 25,499 shares directly. Derivative holdings reflected 112,500 Restricted Stock Units after the transaction, with RSUs vesting 25% annually over four years from grant.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Accuray Incorporated (ARAY) disclosed a director equity grant. On 10/31/2025, a director acquired 354,609 shares of common stock classified as restricted shares under the Accuray Incorporated Amended and Restated 2016 Equity Incentive Plan.

The shares were recorded at a transaction price of $0 and are held directly. Following the transaction, the director beneficially owned 354,609 common shares. The award vests 100% on the first anniversary of the grant date.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

Accuray Incorporated (ARAY) filed a Form S-8 to register shares of common stock for issuance under two stand-alone equity award agreements: an Inducement Restricted Stock Unit Agreement and an Inducement Performance Unit Agreement. These agreements are intended to grant equity awards outside of the company’s existing stock plans.

The filing incorporates by reference Accuray’s Annual Report on Form 10-K for the fiscal year ended June 30, 2025, specified Current Reports on Form 8-K, and the description of its common stock on Form 8-A. It also details standard Delaware law and company bylaw provisions for indemnification of directors and officers, along with related opinion and consent exhibits.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.71%
Tags
registration

FAQ

What is the current stock price of Accuray Incorp (ARAY)?

The current stock price of Accuray Incorp (ARAY) is $0.8597 as of December 25, 2025.

What is the market cap of Accuray Incorp (ARAY)?

The market cap of Accuray Incorp (ARAY) is approximately 97.4M.
Accuray Incorp

Nasdaq:ARAY

ARAY Rankings

ARAY Stock Data

97.44M
108.43M
2.06%
71.26%
1.97%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
MADISON